TY - JOUR
TI - Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study
AU - Taher, A.T.
AU - Karakas, Z.
AU - Cassinerio, E.
AU - Siritanaratkul, N.
AU - Kattamis, A.
AU - Maggio, A.
AU - Rivella, S.
AU - Hollaender, N.
AU - Mahuzier, B.
AU - Gadbaw, B.
AU - Aydinok, Y.
JO - Blood advances
PY - 2018
VL - 131
TODO - 2
SP - 263-265
PB - American Society of Hematology
SN - null
TODO - 10.1182/blood-2017-06-790121
TODO - ferritin;  growth differentiation factor 15;  hepcidin;  iron;  ruxolitinib;  transferrin;  transferrin receptor;  pyrazole derivative;  ruxolitinib, anemia;  beta thalassemia;  clinical article;  drug efficacy;  drug withdrawal;  erythrocyte transfusion;  erythrocyte volume;  erythropoiesis;  ferritin blood level;  fever;  hemoglobin E-beta thalassemia;  hormone blood level;  human;  iron blood level;  iron metabolism;  Letter;  multicenter study;  nuclear magnetic resonance imaging;  open study;  patient safety;  phase 2 clinical trial;  priority journal;  protein blood level;  spleen size;  splenomegaly;  staphylococcal bacteremia;  thalassemia;  toxic hepatitis;  transferrin blood level;  upper respiratory tract infection;  virus pneumonia;  beta thalassemia;  erythroid cell;  thalassemia, beta-Thalassemia;  Erythroid Cells;  Erythropoiesis;  Humans;  Pyrazoles;  Thalassemia
TODO - null
ER -